Home » Stocks » ENZ

Enzo Biochem, Inc. (ENZ)

Stock Price: $3.00 USD 0.14 (4.90%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 143.24M
Revenue (ttm) 96.55M
Net Income (ttm) -10.58M
Shares Out 48.01M
EPS (ttm) -0.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $3.00
Previous Close $2.86
Change ($) 0.14
Change (%) 4.90%
Day's Open 2.89
Day's Range 2.87 - 3.02
Day's Volume 306,632
52-Week Range 1.80 - 4.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Company's specimen collection kit now available for use in COVID-19 testing in the U.S.

2 weeks ago - GlobeNewsWire

NEW YORK, NY, March 17, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today announced that management will present at the KeyBanc Capital Markets...

1 month ago - GlobeNewsWire

Conference call and live webcast scheduled for today, Monday, March 15, 2021 at 4:30 pm (ET)

1 month ago - GlobeNewsWire

NEW YORK, NY, March 04, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that the Company will present at ...

2 months ago - GlobeNewsWire

Conference Call and Webcast Scheduled for March 15, 2021, 4:30 pm ET Conference Call and Webcast Scheduled for March 15, 2021, 4:30 pm ET

2 months ago - GlobeNewsWire

NEW YORK, NY, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent...

3 months ago - GlobeNewsWire

NEW YORK, NY, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that the Enzo Board of Directors h...

3 months ago - GlobeNewsWire

CHEVY CHASE, Md., Jan. 5, 2021 /PRNewswire/ -- Roumell Asset Management, LLC ("Roumell"), which owns 5.78% of the outstanding shares of common stock (the "Common Stock") of Enzo Biochem, Inc. (NYSE: ENZ...

4 months ago - PRNewsWire

- Use of pooled sampling with Enzo's molecular diagnostic technology can help rapidly expand the number of people tested for COVID-19 -

4 months ago - GlobeNewsWire

CHEVY CHASE, Md., Dec. 31, 2020 /PRNewswire/ -- Roumell Asset Management, LLC ("Roumell"), which owns 5.78% of the outstanding shares of common stock of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or "the Co...

4 months ago - PRNewsWire

NEW YORK, NY, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that it has reviewed the position ...

4 months ago - GlobeNewsWire

CHEVY CHASE, Md., Dec. 24, 2020 /PRNewswire/ -- Roumell Asset Management, LLC ("Roumell"), which owns 5.78% of the outstanding shares of common stock of Enzo Biochem, Inc.(NYSE: ENZ) ("Enzo" or "the Com...

4 months ago - PRNewsWire

Enzo Biochem, Inc. has continued to underperform its peers and the general markets despite the tailwind from the pandemic outbreak. In November 2020, two investment funds went activist on the company, d...

4 months ago - Seeking Alpha

Enzo Biochem, Inc. (ENZ) Q1 2021 Results - Earnings Call Transcript

4 months ago - Seeking Alpha

Conference call and live webcast scheduled for today, Wednesday , December 9 , 2020 at 4:30 pm (ET)

4 months ago - GlobeNewsWire

Conference Call and Webcast Scheduled for December 9, 2020, 4:30 pm ET

5 months ago - GlobeNewsWire

NEW YORK, NY, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that Ian B. Walters, MD, has been ...

5 months ago - GlobeNewsWire

NEW YORK, NY, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading biosciences and diagnostics company, announced today that Mary Tagliaferri, MD, has bee...

5 months ago - GlobeNewsWire

Direct-to-Consumer service will initially offer access to COVID-19 molecular and antibody testing and will expand to include other testing in the future

6 months ago - GlobeNewsWire

Enzo Biochem, Inc.'s (ENZ) on Q4 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Conference call and live webcast scheduled for today, Tuesday, October 13, 2020 at 4:30 pm (ET)

6 months ago - GlobeNewsWire

Conference Call and Webcast Scheduled for October 13, 2020, 4:30 pm ET

7 months ago - GlobeNewsWire

Enzo Biochem, Inc: Wildly Undervalued COVID-19 Test Play With Near-Term Catalysts

7 months ago - Seeking Alpha

New initiative introduces Enzo’s Independent Pharmacy Testing Program with full range of products and services to support rapid and accurate testing to more residents of New York State New initiative in...

9 months ago - GlobeNewsWire

Shares of Enzo Biochem Inc. ENZ, +6.71% rallied 7.7% in premarket trading on Monday after the company said it received an emergency use authorization from the Food and Drug Administration for its COVID-...

9 months ago - Market Watch

Authorization Enables Clinical Labs to Purchase and Use Enzo’s AMPIPROBE® SARS-Cov-2 Test System without Further Validation Authorization Enables Clinical Labs to Purchase and Use Enzo’s AMPIPROBE® SARS...

9 months ago - GlobeNewsWire

First Collaboration under Enzo’s School and Institution Testing (“SIT”) Program

10 months ago - GlobeNewsWire

Continues to Explore Opportunities for Use of the Compound as a Potential Treatment for COVID-19

10 months ago - GlobeNewsWire

Enzo Biochem, Inc. (ENZ) Q3 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported results for the third quarter ended April 30, 2020.

10 months ago - GlobeNewsWire

Second Product Offering to Expand Disease Management within Enzo’s Comprehensive COVID-19 Program

11 months ago - GlobeNewsWire

NEW YORK, NY, April 29, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc.  (NYSE: ENZ), a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,624,863 entit...

1 year ago - GlobeNewsWire

Enzo Biochem, Inc. (NYSE: ENZ) shares were rallying Thursday following an update from the company on its comprehensive COVID-19 program.

1 year ago - Benzinga

The COVID-19 outbreak has proved to be a catalyst for biotechs. Some issues that were wallowing in penny stock territory have posted stratospheric gains in the wake of efforts to develop diagnostic test...

Other stocks mentioned: NNVC, OPK, SPEX
1 year ago - Benzinga

Enzo Biochem, Inc. (ENZ) Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Enzo Biochem, Inc. (ENZ) Management on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Enzo Biochem, Inc. (ENZ) Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Enzo Biochem, Inc. (ENZ) Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Enzo Biochem, Inc. (ENZ) President Barry Weiner on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About ENZ

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dye... [Read more...]

Industry
Diagnostics & Research
Founded
1976
CEO
Elazar Rabbani
Employees
408
Stock Exchange
NYSE
Ticker Symbol
ENZ
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Enzo Biochem is 5.50, which is an increase of 83.33% from the latest price.

Price Target
$5.50
(83.33% upside)